SLC5A1 and diabetes mellitus: Moreover, SGLT1 inhibition can inhibit diabetes-induced ROS formation, and dual SGLT-1/2 inhibition by sotagliflozin treatment also shows cardioprotective effect by its antioxidative function [211].